{"nctId":"NCT01516879","briefTitle":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","startDateStruct":{"date":"2012-01-05","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":905,"armGroups":[{"label":"Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Atorvastatin","Drug: Ezetimibe","Other: Diet Only"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Drug: Atorvastatin","Drug: Ezetimibe","Other: Diet Only"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Placebo","otherNames":[]},{"name":"Atorvastatin","otherNames":[]},{"name":"Ezetimibe","otherNames":[]},{"name":"Diet Only","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has provided informed consent.\n* Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:\n\n  * \\< 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk equivalent\n  * \\< 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent\n  * OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO QD and ezetimibe 10 mg PO QD\n* Fasting triglycerides ≤ 400 mg/dL\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular ejection fraction \\< 30%\n* Uncontrolled cardiac arrhythmia\n* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes\n* Uncontrolled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at Week 52","description":"Cholesterol was measured by means of ultracentrifugation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":"1.75"},{"groupId":"OG001","value":"-50.14","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Week 52","description":"Cholesterol was measured by means of ultracentrifugation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"1.9"},{"groupId":"OG001","value":"-52.7","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an LDL-C Response at Week 52","description":"An LDL-C response is defined as LDL-C level \\< 70 mg/dL (1.8 mmol/L) at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"82.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Week 12","description":"Cholesterol was measured by means of ultracentrifugation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.17","spread":"1.31"},{"groupId":"OG001","value":"-54.35","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"0.87"},{"groupId":"OG001","value":"-32.30","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.26","spread":"1.16"},{"groupId":"OG001","value":"-28.18","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.44","spread":"1.68"},{"groupId":"OG001","value":"-41.82","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"1.41"},{"groupId":"OG001","value":"-41.26","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":"1.37"},{"groupId":"OG001","value":"-30.67","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.46","spread":"1.50"},{"groupId":"OG001","value":"-41.75","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.37","spread":"1.62"},{"groupId":"OG001","value":"-27.72","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","spread":"2.39"},{"groupId":"OG001","value":"-2.55","spread":"1.72"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.90"},{"groupId":"OG001","value":"5.77","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52","description":"Cholesterol was measured by means of ultracentrifugation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.89","spread":"4.69"},{"groupId":"OG001","value":"2.74","spread":"3.36"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Week 12 to Week 52 in LDL-C","description":"Cholesterol was measured by means of ultracentrifugation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"1.56"},{"groupId":"OG001","value":"2.44","spread":"1.14"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":302},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Influenza","Back pain"]}}}